KRAS G12C fragment screening renders new binding pockets

References

• Karnoub AE, Weinberg RA. Ras oncogenes: split personalities. Nat Rev Mol Cell Biol. 2008;9:517–531.
   PubMedGoogle Scholar
• Rajalingam K, Schreck R, Rapp UR, et al. Ras oncogenes and their downstream targets. Biochim Biophys Acta. 2007;1773:1177–1195.
   PubMedGoogle Scholar
• Cox AD, Fesik SW, Kimmelman AC, et al. Drugging the undruggable RAS: mission possible? Nat Rev Drug Discov. 2014;13:828–851.
   PubMed Web of Science ®Google Scholar
• Scheffler M, Ihle MA, Hein R, et al. K-ras Mutation Subtypes in NSCLC and Associated Co-occuring Mutations in Other Oncogenic Pathways. J Thorac Oncol. 2019;14:606–616.
   Web of Science ®Google Scholar
• Biankin AV, Waddell N, Kassahn, KS, et al. Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes. Nature. 2012;491:399–405.
   PubMed Web of Science ®Google Scholar
• Cancer Genome Atlas Research, N. Comprehensive molecular profiling of lung adenocarcinoma. Nature. 2014;511(7511):543–550.
   PubMed Web of Science ®Google Scholar
• Neumann J, Zeindl-Eberhart E, Kirchner T, et al. Frequency and type of KRAS mutations in routine diagnostic analysis of metastatic colorectal cancer. Pathol Res Pract. 2009;205:858–862.
   PubMed Web of Science ®Google Scholar
• Hobbs GA, Der CJ, Rossman KL. RAS isoforms and mutations in cancer at a glance. J Cell Sci. 2016;129:1287–1292.
   Google Scholar
• Moore AR, Rosenberg SC, McCormick F, et al. RAS-targeted therapies: is the undruggable drugged? Nat Rev Drug Discov. 2020;19:533–552.
   Google Scholar
• Mott HR, Owen D. Structures of Ras superfamily effector complexes: what have we learnt in two decades? Crit Rev Biochem Mol Biol. 2015;50:85–133.
   PubMed Web of Science ®Google Scholar
• Gasper R, Wittinghofer F. The Ras switch in structural and historical perspective. Biol Chem. 2019;401:143–163.
   PubMed Web of Science ®Google Scholar
• Ganguly AK, Wang Y-S, Pramanik BN, et al. Interaction of a novel GDP exchange inhibitor with the Ras protein. Biochemistry. 1998;37:15631–15637.
   PubMed Web of Science ®Google Scholar
• Palmioli A, Sacco E, Abraham S, et al. First experimental identification of Ras-inhibitor binding interface using a water-soluble Ras ligand. Bioorg Med Chem Lett. 2009;19:4217–4222.
   PubMed Web of Science ®Google Scholar
• Sun Q, Burke JP, Phan J, et al. Discovery of small molecules that bind to K-Ras and inhibit Sos-mediated activation. Angew Chem Int Ed Engl. 2012;51:6140–6143.
   Web of Science ®Google Scholar
• Maurer T, Garrenton LS, Oh A, et al. Small-molecule ligands bind to a distinct pocket in Ras and inhibit SOS-mediated nucleotide exchange activity. Proc Natl Acad Sci U S A. 2012;109:5299–5304.
   Web of Science ®Google Scholar
• Ostrem JM, Peters U, Sos ML, et al. K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions. Nature. 2013;503:548–551.
   PubMed Web of Science ®Google Scholar
• Ostrem JM, Shokat KM. Direct small-molecule inhibitors of KRAS: from structural insights to mechanism-based design. Nat Rev Drug Discov. 2016;15:771–785.
   PubMed Web of Science ®Google Scholar
• Hallin J, Engstrom LD, Hargis L, et al. The KRAS(G12C) Inhibitor MRTX849 Provides Insight toward Therapeutic Susceptibility of KRAS-Mutant Cancers in Mouse Models and Patients, Cancer Discov, 2020; 10(1):54-71.
   Google Scholar
• Shin Y, Jeong JW, Wurz RP, et al. Discovery of N-(1-Acryloylazetidin-3-yl)-2-(1H-indol-1-yl)acetamides as Covalent Inhibitors of KRAS(G12C). ACS Med Chem Lett. 2019;10:1302–1308.
   Web of Science ®Google Scholar
• Canon J, Rex K, Saiki AY, et al. The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity. Nature. 2019;575:217–223.
   PubMed Web of Science ®Google Scholar
• Kettle JG, Bagal SK, Bickerton S, et al. Structure-Based Design and Pharmacokinetic Optimization of Covalent Allosteric Inhibitors of the Mutant GTPase KRAS(G12C), J Med Chem, 2020;63(9):4468-4483.
   Google Scholar
• Fell JB, Fisher JP, Baer BR, et al. Identification of the Clinical Development Candidate MRTX849, a Covalent KRAS(G12C) Inhibitor for the Treatment of Cancer. J Med Chem. 2020;63(13):6679–6693.
   PubMed Web of Science ®Google Scholar
• Ni D, Li X, He X, et al. Drugging K-Ras(G12C) through covalent inhibitors: mission possible? Pharmacol Ther. 2019;202:1–17.
   PubMed Web of Science ®Google Scholar
• Congreve M, Carr R, Murray C, et al. A ‘rule of three’ for fragment-based lead discovery? Drug Discov Today. 2003;8:876–877.
   PubMed Web of Science ®Google Scholar
• Jhoti H, Williams G, Rees DC, et al. The ‘rule of three’ for fragment-based drug discovery: where are we now? Nat Rev Drug Discov. 2013;12:644.
   PubMed Web of Science ®Google Scholar
• Schultes SDG, C.; Haaksma, E.E.J; de Esch I.J.P.; Leurs, R.; Krämer, O. Ligand Efficiency as a guide in fragment hit selection and optimization. Drug Discov Today. 2010;7:e157-e162.
   Google Scholar
• Liu Q, Sabnis Y, Zhao Z, et al. Developing irreversible inhibitors of the protein kinase cysteinome. Chem Biol. 2013;20:146–159.
   Google Scholar
• Weisner J, Gontla R, van der Westhuizen L, et al. Covalent-Allosteric Kinase Inhibitors. Angew Chem Int Ed Engl. 2015;54:10313–10316.
   PubMed Web of Science ®Google Scholar
• Hwang T-L, Shaka AJ. Water suppression that works. Excitation sculpting using arbitrary waveforms and pulsed field gradients. Journal of Magnetic Resonance Series A. 1995;112(2):275–279. https://doi.org/10.1006/jmra.1995.1047
   Google Scholar
• Mayer M, Meyer B. Characterization of Ligand Binding by Saturation Transfer Difference NMR Spectroscopy. Angew Chem Int Ed Engl. 1999;38:1784–1788.
   Web of Science ®Google Scholar
• Bretonnet AS, Jochum A, Walker O, et al. NMR screening applied to the fragment-based generation of inhibitors of creatine kinase exploiting a new interaction proximate to the ATP binding site. J Med Chem. 2007;50:1865–1875.
   PubMed Web of Science ®Google Scholar
• Meinecke R, Meyer B. Determination of the binding specificity of an integral membrane protein by saturation transfer difference NMR: RGD peptide ligands binding to integrin. J Med Chem. 2001;44:3059–3065.
   PubMed Web of Science ®Google Scholar
• Perkins DN, Pappin DJ, Creasy DM, et al. Probability-based protein identification by searching sequence databases using mass spectrometry data. Electrophoresis. 1999;20(3551–67):3551–3567.
   PubMedGoogle Scholar
• Vonrhein C, Flensburg C, Keller P, et al. Data processing and analysis with the autoPROC toolbox. Acta Crystallogr D Biol Crystallogr. 2011;67:293–302.
   PubMedGoogle Scholar
• Winn MD, Ballard CC, Cowtan KD, et al. Overview of the CCP4 suite and current developments. Acta Crystallogr D Biol Crystallogr. 2011;67:235–242.
   Google Scholar
• McCoy AJ, Grosse-Kuntsleve RW, Adams PD, et al. Phaser crystallographic software. J Appl Crystallogr. 2007;40:658–674.
   PubMed Web of Science ®Google Scholar
• Blanc E, Roversi P, Vonrhein C, et al. Refinement of severely incomplete structures with maximum likelihood in BUSTER–TNT. Acta Crystallogr D Biol Crystallogr. 2004;60:2210–2221.
   Google Scholar
• Emsley P, Lohkamp B, Scott WG, et al. Features and development of Coot. Acta Crystallogr D Biol Crystallogr. 2010;66:486–501.
   PubMedGoogle Scholar
• Kessler D, Bergner A, Böttcher J, et al. Drugging all RAS isoforms with one pocket. Future Med Chem. 2020;12(21):1911–1923.
   PubMed Web of Science ®Google Scholar
• Hall BE, Bar-Sagi D, Nassar N. The structural basis for the transition from Ras-GTP to Ras-GDP. Proc Natl Acad Sci U S A. 2002;99:12138–12142.
   Web of Science ®Google Scholar